Topics

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

2020-02-19 18:28:39 | BioPortfolio

Summary

This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.

Study Design

Conditions

Alzheimer Disease

Intervention

Tricaprilin

Status

Not yet recruiting

Source

Cerecin

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-02-19T18:28:39-0500

Clinical Trials [1173 Associated Clinical Trials listed on BioPortfolio]

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease

This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderat...

Study to Compare the Pharmacokinetics of Two Formulations of Tricaprilin and a Placebo on Ketone Body Production

This is Phase 1, Single-center, Single-dose, Placebo-controlled, 3-Way Crossover PK Study recruiting healthy adult male subjects.

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

This is a Phase I, single center, open label, fixed-order, crossover, food-effect, pharmacokinetic (PK) study recruiting healthy, adult, male subjects.

Taste-masking Study for Tricaprilin in Sensory Panelists

This is an open-label multiple-dose study of the taste profile of tricaprilin formulated as a powder for reconstitution.

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

This is a Phase I, open label, randomized, 6-way crossover, pilot PK study

PubMed Articles [15237 Associated PubMed Articles listed on BioPortfolio]

Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.

Numerous results suggest the implication of infectious agents in the onset of Alzheimer's disease (AD).

miR-16-5p and miR-19b-3p prevent amyloid β-induced injury by targeting BACE1 in SH-SY5Y cells.

Alzheimer's disease is the most common neurodegenerative disease, characterized by accumulation of amyloid β peptides. MicroRNAs have been identified as significant regulators and therapeutic targets...

A pilot study of exenatide actions in Alzheimer's disease.

Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease- modifying in Alzheimer's dise...

"Like He's a Kid": Relationality, Family Caregiving, and Alzheimer's Disease.

Spousal caregivers draw upon understandings of shifting relationality to maintain a familial understanding of their spouse with Alzheimer's disease. Working through what it means to think of an adult ...

Cognitive Decline and Alzheimer's Disease in Old Age: A Sex-Specific "Cytokinome Signature".

Elevated peripheral levels of different cytokines and chemokines in subjects with Alzheimer's disease (AD), as compared with healthy controls (HC), have emphasized the role of inflammation in such a d...

Medical and Biotech [MESH] Definitions

Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.

Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.

A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION, POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.

More From BioPortfolio on "Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial